Astrazeneca (AZN) Profit After Tax (2009 - 2026)

Astrazeneca (AZN) has reported Profit After Tax for 18 consecutive years, with $3.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 5.48% year-over-year to $3.1 billion; the TTM figure through Mar 2026 stood at $10.4 billion (up 33.55% YoY), while the FY2025 annual figure was $10.2 billion, up 45.33% from the prior year.
• Profit After Tax came in at $3.1 billion for Q1 2026 at Astrazeneca, up from $2.3 billion in the prior quarter.
• The five-year high for Profit After Tax was $3.1 billion in Q1 2026, with the low at $360.0 million in Q2 2022.
• Average Profit After Tax over 5 years is $1.7 billion, with a median of $1.8 billion recorded in 2023.
• Across the five-year window, Profit After Tax tumbled 68.56% in 2022 and surged 405.56% in 2023, its largest moves.
• Year by year, Profit After Tax stood at $902.0 million in 2022, then grew by 6.32% to $959.0 million in 2023, then jumped by 56.41% to $1.5 billion in 2024, then soared by 55.27% to $2.3 billion in 2025, then surged by 32.29% to $3.1 billion in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $3.1 billion, $2.3 billion, and $2.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.